Ac-SDKP Side Effects: Safety Signals and Warnings
Ac-SDKP safety concerns are compound-specific. The main listed side effects are No significant adverse effects reported in preclinical studies, Theoretical hypotensive effect at high doses, and Very limited human safety data. The main warning signals are Not approved for clinical use, Extremely short half-life limits practical application, and Endogenous levels are regulated by ACE; exogenous supplementation effects are not fully characterized.
Direct Answer
Evidence for Ac-SDKP is too preliminary to support a research protocol with confidence. Despite interest from multiple independent research groups in fibrosis biology, there are no clinical trials in humans. The anti-fibrotic mechanism is scientifically credible, but without pharmacokinetic data, dosing guidance, or safety data in humans, there is no basis for a therapeutic protocol.
- Evidence grade
- Level D
- Research status
- Preclinical
- Category
- Healing & Recovery
- Best for
- Anti-fibrotic mechanistic research, kidney and cardiac fibrosis models (preclinical only)
Reported Side Effects
- No significant adverse effects reported in preclinical studies
- Theoretical hypotensive effect at high doses
- Very limited human safety data
Warnings
- Not approved for clinical use
- Extremely short half-life limits practical application
- Endogenous levels are regulated by ACE; exogenous supplementation effects are not fully characterized
- All evidence is predominantly preclinical
Known or Plausible Interactions
- ACE inhibitors (ACE inhibitors increase endogenous Ac-SDKP levels by preventing its degradation)
- Chemotherapy agents (may protect stem cells from cytotoxicity)
- Angiotensin receptor blockers (do not affect Ac-SDKP levels)
Regulatory Context
Ac-SDKP is a research compound not approved for clinical use in any country. It is not a controlled substance. Available for research purposes only.
Evidence Snapshot
| Evidence grade | Level D |
|---|---|
| Research status | Preclinical |
| Best supported outcomes | Hematopoietic Stem Cell Protection (Level C), Cardiac Anti-Fibrosis (Level D), and Renal Fibrosis Prevention (Level D) |
| Primary citation count | 3 |
| Last reviewed | 2026-06-02 |
Related Guides
How to Cite This Page
ExaminePeptides. "Ac-SDKP Side Effects: Safety Signals and Warnings." Last reviewed 2026-06-02. https://examinepeptides.com/answers/ac-sdkp-side-effects-safety/
This static answer page is built for fast indexing and direct citation. It summarizes the matching full evidence review and links back to primary sources where the source database includes them.